Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a ...
Q1 2026
May 14, 2026
FY 2025
Mar 23, 2026
Q4 2025
Q3 2025
Nov 10, 2025
Q2 2025
Aug 7, 2025